Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia

Peter D. Cole, Barton A. Kamen

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the components of leukemia therapy can contribute to adverse neurologic sequelae, including craniospinal irradiation, nucleoside analogs, corticosteroids, and antifolates. In this review, we describe the characteristic radiographic findings and neurocognitivie deficits seen among survivors of childhood ALL. We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity, with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system. Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence.

Original languageEnglish (US)
Pages (from-to)174-183
Number of pages10
JournalMental Retardation and Developmental Disabilities Research Reviews
Volume12
Issue number3
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Craniospinal Irradiation
Folic Acid Antagonists
Therapeutics
Nucleosides
Folic Acid
Nervous System
Adrenal Cortex Hormones
Leukemia
Central Nervous System
Incidence

Keywords

  • Homocysteine
  • Leukoencephalopathy
  • Methotrexate
  • Neurotoxicity
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neuropsychology and Physiological Psychology
  • Genetics(clinical)

Cite this

Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. / Cole, Peter D.; Kamen, Barton A.

In: Mental Retardation and Developmental Disabilities Research Reviews, Vol. 12, No. 3, 2006, p. 174-183.

Research output: Contribution to journalArticle

@article{a080eb92ef004d5daa6c0bf079acc0af,
title = "Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia",
abstract = "Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the components of leukemia therapy can contribute to adverse neurologic sequelae, including craniospinal irradiation, nucleoside analogs, corticosteroids, and antifolates. In this review, we describe the characteristic radiographic findings and neurocognitivie deficits seen among survivors of childhood ALL. We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity, with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system. Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence.",
keywords = "Homocysteine, Leukoencephalopathy, Methotrexate, Neurotoxicity, S-adenosylmethionine",
author = "Cole, {Peter D.} and Kamen, {Barton A.}",
year = "2006",
doi = "10.1002/mrdd.20113",
language = "English (US)",
volume = "12",
pages = "174--183",
journal = "Mental Retardation and Developmental Disabilities Research Reviews",
issn = "1080-4013",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia

AU - Cole, Peter D.

AU - Kamen, Barton A.

PY - 2006

Y1 - 2006

N2 - Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the components of leukemia therapy can contribute to adverse neurologic sequelae, including craniospinal irradiation, nucleoside analogs, corticosteroids, and antifolates. In this review, we describe the characteristic radiographic findings and neurocognitivie deficits seen among survivors of childhood ALL. We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity, with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system. Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence.

AB - Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the components of leukemia therapy can contribute to adverse neurologic sequelae, including craniospinal irradiation, nucleoside analogs, corticosteroids, and antifolates. In this review, we describe the characteristic radiographic findings and neurocognitivie deficits seen among survivors of childhood ALL. We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity, with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system. Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence.

KW - Homocysteine

KW - Leukoencephalopathy

KW - Methotrexate

KW - Neurotoxicity

KW - S-adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=33750481552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750481552&partnerID=8YFLogxK

U2 - 10.1002/mrdd.20113

DO - 10.1002/mrdd.20113

M3 - Article

VL - 12

SP - 174

EP - 183

JO - Mental Retardation and Developmental Disabilities Research Reviews

JF - Mental Retardation and Developmental Disabilities Research Reviews

SN - 1080-4013

IS - 3

ER -